0001209191-23-020291.txt : 20230321
0001209191-23-020291.hdr.sgml : 20230321
20230321164436
ACCESSION NUMBER: 0001209191-23-020291
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230320
FILED AS OF DATE: 20230321
DATE AS OF CHANGE: 20230321
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Al-Wakeel Yasir B.
CENTRAL INDEX KEY: 0001650691
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40674
FILM NUMBER: 23750191
MAIL ADDRESS:
STREET 1: MERRIMACK PHARMACEUTICALS, INC.
STREET 2: ONE KENDALL SQUARE, SUITE B7201
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MAXCYTE, INC.
CENTRAL INDEX KEY: 0001287098
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
IRS NUMBER: 522210438
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 22 FIRSTFIELD ROAD
STREET 2: SUITE 250
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
BUSINESS PHONE: 301-517-5556
MAIL ADDRESS:
STREET 1: 22 FIRSTFIELD ROAD
STREET 2: SUITE 250
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
FORMER COMPANY:
FORMER CONFORMED NAME: MAXCYTE INC
DATE OF NAME CHANGE: 20040415
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-03-20
0
0001287098
MAXCYTE, INC.
MXCT
0001650691
Al-Wakeel Yasir B.
C/O MAXCYTE, INC.
9713 KEY WEST AVENUE, SUITE 400
ROCKVILLE
MD
20850
1
0
0
0
0
Stock Option (right to buy)
4.19
2023-03-20
4
A
0
40000
0.00
A
2033-03-19
Common Stock
40000
40000
D
This grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. 23,333 of the shares underlying this option vested on March 20, 2023 and the remaining 16,667 shares will vest in 15 equal monthly installments thereafter, beginning on April 14, 2023, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
/s/ Brian F. Leaf, Attorney-in-Fact
2023-03-21